^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | flotetuzumab (MGD006) (CD3 agonist, CD123 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML "
Published date:
11/04/2020
Excerpt:
Finally, 7 out of 15 patients (47%) with R/R AML and TP53 abnormalities showed complete responses to flotetuzumab (<5% BM blasts)...Patients with TP53 abnormalities who achieved a complete response experienced prolonged survival (median, 10.3 months; range, 3.3-21.3 months).
DOI:
https://doi.org/10.1182/bloodadvances.2020002512
Source:
Title:
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Published date:
10/27/2020
Excerpt:
We therefore correlated TP53 mutational status with immune landscapes and with complete responses to flotetuzumab in a cohort of 45 patients with R/R AML, including 15 patients with TP53 mutations and/or chromosome 17p deletions...Overall response rate (ORR: CR, CRi, MLFS, or partial response) in patients with TP53 mutations and/or 17p abnormalities was 60% (9/15), with 47% (7/15) achieving complete response (<5% BM blasts on study; Figure 6B).
DOI:
10.1182/bloodadvances.2020002512
